Drug intelligence / Profile preview

c-Kit-targeting antibody

Development stage
Unknown
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous, Subcutaneous
01

Overview

A c-Kit-targeting antibody is a monoclonal antibody designed to bind to and inhibit c-Kit (also known as CD117 or stem cell factor receptor), a receptor tyrosine kinase. c-Kit is expressed on hematopoietic stem cells, mast cells, melanocytes, and various cancer cells. Activation of c-Kit by its ligand, stem cell factor (SCF), promotes cell survival, proliferation, and differentiation. Antibodies targeting c-Kit are developed for therapeutic applications such as conditioning regimens for hematopoietic stem cell transplantation (by depleting endogenous stem cells), and the treatment of mast cell-mediated allergic or inflammatory diseases (like chronic urticaria) and c-Kit-positive malignancies (such as gastrointestinal stromal tumors and small cell lung cancer).

Other names
anti-CD117 antibodyanti-CD-117 antibodyanti-CD 117 antibodyanti-CD117 monoclonal antibodyanti-CD-117 monoclonal antibodyanti-CD 117 monoclonal antibodyanti-c-Kit antibodyanti-c-Kit monoclonal antibodyc-Kit-targeting monoclonal antibody
02

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)SCF (Stem cell factor)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on c-Kit-targeting antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on c-Kit-targeting antibody.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call